Blog
Protein Targets and Training Strategy on Semaglutide or Retatrutide
Stephen M. Walker II • March 29, 2026
The scale can move fast on semaglutide and even faster on retatrutide. That does not mean the cut is going well. In the STEP 1 DXA substudy, semaglutide 2.4 mg reduced total fat mass by 8.36 kg and total lean mass by 5.26 kg over 68 weeks. In the 2025 Lancet Diabetes & Endocrinology retatrutide substudy, the authors concluded that the proportion of lean-mass loss to weight loss was similar to other obesity treatments despite larger total fat-mass reduction.12
That is the real coaching problem on these drugs. Appetite suppression makes adherence easier. It also makes under-fueling easier. If protein drops, training quality falls, and rate of loss gets too aggressive, the medication starts pulling against your physique goal instead of supporting it. If you need the broader medication setup first, start with the GLP-1 diet guide, the full GLP-1 muscle-preservation guide, and the peptide overview Peptides for Body Recomposition that separates approved obesity drugs from tesamorelin, collagen, and research-only compounds. If you want the men-25-55 lifting version with a stricter protein floor and rate-of-loss guardrails, read How to Prevent Muscle Loss on GLP-1s: A Men's Protein Guide. This article is the tighter execution layer. How do you set protein and training so the weight you lose is mostly fat.
What changes on these drugs
These medications change the job each meal has to do. Hunger is lower. Meal size tolerance is lower. High-fat meals often feel worse. Long gaps between meals become easy to miss because you do not get the same appetite signal telling you to correct course. For approved obesity treatment today, most readers are really comparing semaglutide with tirzepatide, both inside the broader GLP-1 receptor agonist conversation about appetite suppression, protein sufficiency, and lean-mass retention.
That pattern pushes people toward a predictable failure mode. They eat two small meals, drink coffee, walk more, praise the scale, and wonder why their lifts feel flat three weeks later. The drug did not create the muscle loss on its own. The drug made low intake easy enough to sustain.
As of March 29, 2026, semaglutide is an approved medication used in obesity and diabetes care. Retatrutide remains investigational, even though Lilly has already reported positive Phase 3 topline results in type 2 diabetes and osteoarthritis-linked obesity programs.3 For practical nutrition planning, the distinction matters less than people think. Retatrutide appears to require tighter guardrails because appetite suppression and weight loss can be stronger.
What the evidence actually says about lean mass
Lean-mass loss is not unique to GLP-1-class therapy. It happens in diet-induced weight loss, bariatric surgery, and any other successful reduction in body mass. The question is the ratio.
The semaglutide evidence is easiest to read because the body-composition data are now broad enough to show two things at once. In STEP 1, lean mass fell in absolute kilograms, yet lean mass as a proportion of body weight increased because fat mass fell more.1 In the 2025 SEMALEAN study, semaglutide reduced body weight, fat mass, visceral fat, and appendicular skeletal muscle mass over 12 months, but muscle-function measures gave a more restrained picture than the alarmist headlines imply.4
Retatrutide points in the same direction. The 2025 substudy in adults with type 2 diabetes showed fat-mass reductions of 15.2% at pooled 4 mg, 26.1% at pooled 8 mg, and 23.2% at 12 mg by week 36. The authors stated that lean-mass loss relative to total weight loss looked similar to other obesity treatments, which matters because retatrutide is the drug most likely to trigger panic about muscle loss simply because total weight loss can be so large.2
The prevention logic is straightforward. You will almost never eliminate lean-mass loss during a productive fat-loss phase. You can shift the ratio in your favor with adequate protein, repeated mechanical tension from lifting, and a rate of loss that your training can survive.
The protein floor
The 2025 multi-society advisory on nutritional priorities during GLP-1 therapy recommends protein intake in the range of 1.2 to 1.6 g/kg adjusted body weight per day, with strength training, as the baseline muscle-preservation floor for people using these medications.5 That is a good starting range for the average patient. It is not the full answer for every active person.
If you lift seriously, diet aggressively, or already sit at a lower body-fat level, the sports-nutrition literature pushes the useful range upward. Meta-analysis and deficit-era trials continue to support higher intakes for lean-mass retention in trained populations, often landing around 1.6 to 2.2 g/kg and sometimes higher in aggressive cuts.67
The practical move is to separate medication users into contexts rather than pretend one number fits everyone.
| Context | Semaglutide daily protein target | Retatrutide daily protein target | Why the target shifts |
|---|---|---|---|
| General fat-loss user | 1.2 to 1.6 g/kg | 1.4 to 1.8 g/kg | The advisory floor works for semaglutide. Retatrutide usually needs a larger buffer because low intake is easier to drift into |
| Active lifter in a deficit | 1.6 to 2.2 g/kg | 1.8 to 2.4 g/kg | Training raises the payoff from protein and dieting raises the cost of under-eating it |
| Older adult | 1.4 to 2.0 g/kg | 1.6 to 2.2 g/kg | Anabolic resistance and low appetite create a double problem |
| Endurance athlete using the drug for weight loss | 1.4 to 2.0 g/kg | 1.6 to 2.2 g/kg | Recovery demand stays high even when appetite is low |
The highest end of those ranges is a coaching inference from the wider protein and energy-deficit literature. The medication-specific advisory gives the floor. Training status decides whether you should stop there.
Per-meal protein matters more here than in a normal cut
People on these drugs often assume the daily total is the whole job. It is not. Low appetite changes meal size, which means meal-level protein can collapse even if the daily average looks fine on the better days.
This is where protein distribution and the leucine threshold matter. Most active adults should aim for 0.3 to 0.5 g/kg per meal with at least three clear protein feedings. Older adults and plant-based eaters often need the high end of that range. The goal is to create repeated muscle-protein-synthesis pulses instead of one large dinner and two nutritionally empty halves of a day.
| Body weight | Per-meal protein target | Daily structure that usually works |
|---|---|---|
| 60 kg | 25 to 35 g | 3 meals of 25 to 30 g plus 1 protein snack if needed |
| 75 kg | 30 to 40 g | 3 meals of 30 to 40 g plus post-training or pre-sleep protein |
| 90 kg | 35 to 45 g | 4 feedings of 35 to 45 g |
| 105 kg | 40 to 50 g | 4 feedings of 40 to 50 g, often with one liquid protein serving |
Liquid protein deserves more respect on semaglutide and retatrutide than it gets in ordinary meal-planning advice. A shake is not nutritionally superior to solid food. It is mechanically easier to finish when appetite is low. That makes it useful. Greek yogurt, whey, casein, milk, soy isolate, cottage cheese, and blended fruit-plus-protein meals all solve the same problem. They raise protein density without forcing a huge meal volume.
If you are deciding whether creatine belongs in the same setup, use Creatine While on GLP-1: Worth It for Fat Loss and Strength? for the supplement-specific call on training payoff, scale noise, and dose strategy when appetite is low.
Semaglutide versus retatrutide in practice
The training idea is similar on both drugs. The feeding strategy is where the split becomes obvious.
| Variable | Semaglutide | Retatrutide |
|---|---|---|
| Appetite suppression | Strong | Often stronger |
| Protein floor that usually works | Often manageable with 3 meals and 1 planned snack | Often easier with 2 solid meals plus 1 to 2 liquid protein feedings |
| Rate-of-loss guardrail | Usually keep losses around 0.5 to 1.0% of body weight per week | Usually tighten to 0.5 to 0.8% when performance matters |
| Carbohydrate around training | Useful | Usually more protective because the margin for under-fueling is smaller |
| Need for rigid meal defaults | Moderate | High |
This is why retatrutide users often need a more deliberate pre-workout and post-workout routine. If total intake collapses, you are not only risking lean tissue. You are risking sessions poor enough that the body stops receiving a reason to hold muscle in the first place.
Training strategy that actually works
Walking is good for health, adherence, and energy expenditure. It is not the primary muscle-retention tool on these medications. Resistance training is.
The rule is simple. Keep intensity. Trim volume only when recovery demands it. In practice that means you should keep loads, effort, and exercise selection close to your normal training plan, then reduce sets before you reduce tension. Replacing a hard lower-body day with more steps is a body-composition downgrade for anyone who cares about lean mass.
| Training context | What to keep | What to reduce first | What to protect nutritionally |
|---|---|---|---|
| Beginner lifter | 2 to 3 full-body sessions each week with compound lifts | Extra accessory volume | Protein consistency and a small carb feeding before training |
| Intermediate lifter in a cut | 3 to 4 sessions with hard top sets still present | Junk volume and failure work | Pre-workout carbs, post-workout protein, sleep |
| Older adult | 2 to 4 sessions with machine or free-weight patterns that load major muscle groups | High-soreness novelty | Protein at breakfast and after training |
| Endurance athlete | 2 lifting sessions kept year-round | Secondary conditioning that competes with recovery | Carbs during key sessions and a stable protein floor |
If a session feels flat once, that is noise. If bar speed, rep quality, and willingness to train are down for two straight weeks, assume under-fueling before assuming you need a smarter split. These drugs change your appetite faster than they change your physiology.
Carbohydrate still matters
Protein preserves tissue. Carbohydrate protects training quality. People on semaglutide or retatrutide often under-eat both, then try to solve the whole problem with more protein powder.
That misses the mechanism. Muscle is preserved best when protein intake is adequate and training quality stays high enough to create repeated anabolic demand. If you train with no usable glycogen, session quality drops. If session quality drops, the return on your protein target drops with it.
| Session type | Minimum pre-workout intake that usually works | Post-workout intake |
|---|---|---|
| Normal lifting day | 20 to 30 g carbs plus 15 to 25 g protein | 30 to 40 g protein within 2 hours |
| Hard lower-body or high-volume session | 30 to 50 g carbs plus 20 to 30 g protein | 35 to 45 g protein plus 30 to 50 g carbs |
| Low-appetite day | 15 to 20 g fast carbs plus any tolerable protein format | 25 to 35 g protein even if appetite is poor |
On retatrutide, these meals often need to be simpler and smaller. Rice, yogurt, fruit, toast, milk, cereal, shakes, soups, and lean-protein bowls tend to work better than dense restaurant meals. Use the food form that gets the target done.
Low-appetite meal architecture
Most failures on these drugs happen on the days when nothing sounds good. Plan those days before they happen.
| Situation | Better move | Worse move |
|---|---|---|
| Breakfast feels impossible | Drink 25 to 35 g whey or milk-based protein with fruit | Skip the meal and promise yourself a larger lunch |
| Lunch appetite is weak | Use a small protein bowl, wrap, yogurt, or soup plus easy carbs | Order a large salad with little protein and call it disciplined |
| Pre-workout feels heavy | Use banana, toast, cereal, or sports drink plus light protein | Train fasted and hope the medication carries the session |
| Dinner fullness arrives early | Start with the protein source first | Eat vegetables first, get full, and miss the main target |
This is one place where protein quality matters more than usual. Small meals need dense, complete protein. Eggs alone are often too small. Collagen does not count as a primary meal protein. Tiny portions of beans or oats do not solve the leucine problem. Build the meal around a source that can actually hit the target.
If you need copy-paste meal structures instead of more theory, read Meal Templates for Low Appetite Days: High-Protein, Low-Volume Options for the exact shake, bowl, roll, and soup patterns that survive the worst appetite days.
Monitoring rules that save people months of wasted cutting
The mirror is slow. The scale is noisy. Training logs usually tell the truth first.
| Signal | What it usually means | Correction |
|---|---|---|
| Weight loss above 1.0% body weight per week for 2 to 3 weeks on semaglutide | Deficit is likely too aggressive for muscle retention | Raise calories by 100 to 250 per day, usually around training |
| Weight loss above 0.8% body weight per week for 2 to 3 weeks on retatrutide | Under-fueling risk is high | Raise calories and reduce unnecessary cardio first |
| Strength down across 2 key lifts for 2 weeks | Recovery and fuel are too low | Audit protein, pre-workout carbs, and sleep before changing program design |
| Repeated days under 60 to 80 g protein | Meal architecture is failing | Add default liquid protein feedings immediately |
| Constipation, dizziness, or persistent nausea | Tolerance and hydration are limiting intake | Simplify meals, raise fluids, slow the fiber ramp, and discuss dosing or symptom management with your clinician |
If you want one clean metric stack, use these four. Daily scale weight, 14-day weight trend, protein grams, and performance on 2 to 4 anchor lifts. That stack catches nearly every meaningful problem early.
The mistakes that keep showing up
The useful rule is this. Start with the medication-specific floor. Build three or four protein feedings that survive your low-appetite days. Keep lifting hard enough to give your body a reason to stay muscular. If the scale is falling faster than your training can tolerate, slow the cut before the drug turns a successful fat-loss phase into a weak one.
The biggest errors here come from misreading the drug's signals. Rapid weight loss looks rewarding, so people celebrate the scale before they check what happened to training performance. Low hunger then looks like proof that eating less is always better, when it is really a drug effect rather than feedback that your body no longer needs protein.
Execution problems usually show up next. Shakes help with meal completion, but they do not automatically solve total calories, carbohydrate placement, or training quality. Lifting also feels harder on these drugs, so some people replace it with cardio and steps. Harder is expected. Lower quality is the signal to adjust fuel and fatigue, not to remove the main lean-mass stimulus.
Generic protein targets also break down fast on a GLP-1. The right number for a sedentary patient on semaglutide is not the right number for a lifter cutting on retatrutide. Match the floor to the medication, the training load, and the amount of lean mass you are trying to protect.
Next step
If you need the full medication setup first, start with the GLP-1 diet guide
If you want the complete men’s recomposition playbook, read How to Prevent Muscle Loss on GLP-1s: A Men's Protein Guide
If you want the broader evidence filter that separates obesity drugs from research peptides and collagen, use Peptides for Body Recomposition
Jensen T, Sattar N, McGowan B, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17.
↩Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684.
↩Eli Lilly and Company. Retatrutide news and trial updates. Accessed March 29, 2026.
↩SEMALEAN study. Obesity. 2025.
↩Fitch A, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025.
↩Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376-384.
↩Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body mass loss during weight loss in athletes. Med Sci Sports Exerc. 2010;42(2):326-337.
↩